المؤلفون: Majem, M., Forster, M. D., Krebs, Matthew G, Peguero, J., Clay, T. D., Felip, E., Iams, W., Roxburgh, P., de Speville, B. D., Bajaj, P., Mueller, C., Triebel, F.

المساهمون: Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

العلاقة: https://dx.doi.org/10.1016/S1556-0864Test(23)00265-4; Majem M, Forster MD, Krebs MG, Peguero J, Clay TD, Felip E, et al. Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors. Journal of Thoracic Oncology. 2023 Apr;18(4):S43-S4. PubMed PMID: WOS:000995007600012.; http://hdl.handle.net/10541/626400Test; Journal of Thoracic Oncology

الإتاحة: https://doi.org/10.1016/S1556-0864Test(23)00265-4
http://hdl.handle.net/10541/626400Test

المؤلفون: Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Jr., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., Bowyer, S., de Miguel, M., Han, S. W., Krebs, Matthew G, Lee, J. S., Cheng, M. L., Arbour, K., Massarelli, E., Choi, Y., Shi, Z., Mandlekar, S., Lin, M. T., Royer-Joo, S., Chang, J., Dharia, N. V., Schutzman, J. L., Desai, J.

المساهمون: Princess Margaret Cancer Centre, University Health Network, and the Departments of Medicine and Immunology, University of Toronto, Toronto

العلاقة: https://doi.org/10.1056/NEJMoa2303810Test; Sacher A, LoRusso P, Patel MR, Miller WH, Jr., Garralda E, Forster MD, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. The New England journal of medicine. 2023 Aug 24;389(8):710-21. PubMed PMID: 37611121. Epub 2023/08/23. eng.; http://hdl.handle.net/10541/626533Test; New England Journal of Medicine

الإتاحة: https://doi.org/10.1056/NEJMoa2303810Test
http://hdl.handle.net/10541/626533Test

المؤلفون: Lechner, M., Takahashi, Y., Turri-Zanoni, M., Ferrari, M., Liu, J., Counsell, N., Mattavelli, D., Rampinelli, V., Vermi, W., Lombardi, D., Saade, R., Park, K. W., Schartinger, V. H., Franchi, A., Facco, C., Sessa, F., Battocchio, S., Fenton, T. R., Vaz, F. M., O'Flynn, P., Howard, D., Stimpson, P., Wang, S., Hannan, S. A., Unadkat, S., Hughes, J., Dwivedi, R., Forde, C. T., Randhawa, P., Gane, S., Joseph, J., Andrews, P. J., Dave, M., Fleming, J. C., Thomson, David J, Zhu, T., Teschendorff, A., Royle, G., Steele, C., Jimenez, J. E., Laco, J., Wang, E. W., Snyderman, C., Lacy, P. D., Woods, R., O'Neill, J. P., Saraswathula, A., Kaur, R. P., Zhao, T., Ramanathan, M., Jr., Gallia, G. L., London, N. R., Jr., Le, Q. T., West, R. B., Patel, Z. M., Nayak, J. V., Hwang, P. H., Hermsen, M., Llorente, J., Facchetti, F., Nicolai, P., Bossi, P., Castelnuovo, P., Jay, A., Carnell, D., Forster, M. D., Bell, D. M., Lund, V. J., Hanna, E. Y.

المساهمون: UCL Cancer Institute, University College London, London, United Kingdom

العلاقة: https://dx.doi.org/10.1055/s-0042-1750178Test; Lechner M, Takahashi Y, Turri-Zanoni M, Ferrari M, Liu J, Counsell N, et al. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. Journal of neurological surgery Part B, Skull base. 2023 Aug;84(4):307-19. PubMed PMID: 37405239. Pubmed Central PMCID: PMC10317567. Epub 2023/07/05. eng.; http://hdl.handle.net/10541/626437Test; Journal of Neurological Surgery, Part B; Skull Base

الإتاحة: https://doi.org/10.1055/s-0042-1750178Test
http://hdl.handle.net/10541/626437Test

المؤلفون: Al Bakir, M., Huebner, A., Martinez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., Moore, D. A., Veeriah, S., Ward, S., Laycock, J., Johnson, D., Rowan, A., Razaq, M., Akther, M., Naceur-Lombardelli, C., Prymas, P., Toncheva, A., Hessey, S., Dietzen, M., Colliver, E., Frankell, A. M., Bunkum, A., Lim, E. L., Karasaki, T., Abbosh, C., Hiley, C. T., Hill, M. S., Cook, D. E., Wilson, G. A., Salgado, R., Nye, E., Stone, R. K., Fennell, D. A., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Summers, Yvonne J, Lindsay, Colin R, Blackhall, Fiona H, Cave, J., Blyth, K. G., Nair, A., Ahmed, A., Taylor, M. N., Procter, A. J., Falzon, M., Lawrence, D., Navani, N., Thakrar, R. M., Janes, S. M., Papadatos-Pastos, D., Forster, M. D., Lee, S. M., Ahmad, T., Quezada, S. A., Peggs, K. S., Van Loo, P., Dive, Caroline, Hackshaw, A., Birkbak, N. J., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C., Lester, J. F., Bajaj, A., Nakas, A., Sodha-Ramdeen, A., Ang, K., Tufail, M., Chowdhry, M. F., Scotland, M., Boyles, R., Rathinam, S., Wilson, C., Marrone, D., Dulloo, S., Matharu, G., Shaw, J. A., Riley, J., Primrose, L., Boleti, E., Cheyne, H., Khalil, M., Richardson, S., Cruickshank, T., Benafif, S., Gilbert, K., Patel, A. J., Osman, A., Lacson, C., Langman, G., Shackleford, H., Djearaman, M., Kadiri, S., Leek, A., Hodgkinson, J. D., Totten, N., Montero, A., Smith, E., Fontaine, E., Granato, F., Doran, H., Novasio, J., Rammohan, K., Joseph, L., Bishop, P., Shah, R., Moss, S., Joshi, V., Crosbie, P., Gomes, F., Brown, K., Carter, M., Chaturvedi, A., Priest, L., Oliveira, P., Krebs, M. G., Clipson, A., Tugwood, J., Kerr, A., Rothwell, D. G., Kilgour, E., Aerts, H., Schwarz, R. F., Kaufmann, T. L., Rosenthal, R., Szallasi, Z., Kisistok, J., Sokac, M., Diossy, M., Demeulemeester, J., Stewart, A., Magness, A., Karamani, A., Chain, B., Campbell, B. B., Castignani, C., Bailey, C., Puttick, C., Weeden, C. E., Lee, C., Richard, C., Pearce, D. R., Karagianni, D., Biswas, D., Levi, D., Hoxha, E., Cadieux, E. L., Gronroos, E., Galvez-Cancino, F., Athanasopoulou, F., Gimeno-Valiente, F., Kassiotis, G., Stavrou, G., Mastrokalos, G., Zhai, H. R., Lowe, H. L., Matos, I., Goldman, J., Reading, J. L., Black, J. R. M., Herrero, J., Rane, J. K., Nicod, J., Lam, J. M., Hartley, J. A., Enfield, K. S. S., Selvaraju, K., Thol, K., Litchfield, K., Ng, K. W., Chen, K. Z., Dijkstra, K., Thakkar, K., Ensell, L., Shah, M., Vasquez, M., Litovchenko, M., Sunderland, M. W., Leung, M., Escudero, M., Angelova, M., Tanic, M., Sivakumar, M., Kanu, N., Chervova, O., Lucas, O., Al-Sawaf, O., Hobson, P., Pawlik, P., Bentham, R., Hynds, R. E., Vendramin, R., Saghafinia, S., Lopez, S., Gamble, S., Ung, S. K. A., Vanloo, S., Boeing, S., Beck, S., Bola, S. K., Denner, T., Marafioti, T., Mourikis, T. P., Spanswick, V., Barbe, V., Lu, W. T., Hill, W., Liu, W. K., Wu, Y., Naito, Y., Ramsden, Z., Veiga, C., Royle, G., Collins-Fekete, C. A., Fraioli, F., Ashford, P., Clark, T., Borg, E., Wilson, J., Patrini, D., Hoogenboom, E. M., Monk, F., Holding, J. W., Choudhary, J., Bhakhri, K., Scarci, M., Hayward, M., Panagiotopoulos, N., Gorman, P., Khiroya, R., Stephens, R. C. M., Wong, Y. N. S., Bandula, S., Sharp, A., Smith, S., Gower, N., Dhanda, H. K., Chan, K., Pilotti, C., Leslie, R., Grapa, A., Zhang, H. Y., AbdulJabbar, K., Pan, X. X., Yuan, Y. Y., Chuter, D., MacKenzie, M., Chee, S., Alzetani, A., Scarlett, L., Richards, J., Ingram, P., Austin, S., Lim, E., De Sousa, P., Jordan, S., Rice, A., Raubenheimer, H., Bhayani, H., Ambrose, L., Devaraj, A., Chavan, H., Begum, S., Buderi, S. I., Kaniu, D., Malima, M., Booth, S., Nicholson, A. G., Fernandes, N., Shah, P., Proli, C., Hewish, M., Danson, S., Shackcloth, M. J., Robinson, L., Russell, P., Dick, C., Le Quesne, J., Kirk, A., Asif, M., Bilancia, R., Kostoulas, N., Thomas, M.

المساهمون: Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London

العلاقة: https://dx.doi.org/10.1038/s41586-023-05729-xTest; Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 2023 Apr. PubMed PMID: WOS:000991048500004.; http://hdl.handle.net/10541/626391Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05729-xTest
http://hdl.handle.net/10541/626391Test

المؤلفون: Pruis, M. A., Krebs, Matthew G, Plummer, R., De Vos, F., Angevin, E., Prenen, H., Forster, M. D., Clack, G., Van der Aa, A., Tjwa, M., Jansen, E., Perera, T., Lolkema, M. P.

المساهمون: Department of Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

العلاقة: https://dx.doi.org/10.1093/oncolo/oyad146Test; Pruis MA, Krebs MG, Plummer R, De Vos F, Angevin E, Prenen H, et al. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. Oncologist. 2023 Jun 1. PubMed PMID: 37260332. Epub 2023/06/01. eng.; http://hdl.handle.net/10541/626339Test; Oncologist

الإتاحة: https://doi.org/10.1093/oncolo/oyad146Test
http://hdl.handle.net/10541/626339Test

المؤلفون: Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., Hill, M. S., Grigoriadis, K., Moore, D. A., Black, J. R. M., Liu, W. K., Thol, K., Pich, O., Watkins, T. B. K., Naceur-Lombardelli, C., Cook, D. E., Salgado, R., Wilson, G. A., Bailey, C., Angelova, M., Bentham, R., Martínez-Ruiz, C., Abbosh, C., Nicholson, A. G., Le Quesne, J., Biswas, D., Rosenthal, R., Puttick, C., Hessey, S., Lee, C., Prymas, P., Toncheva, A., Smith, J., Xing, W., Nicod, J., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Blyth, K. G., Fennell, D. A., Forster, M. D., Lee, S. M., Falzon, M., Hewish, M., Shackcloth, M. J., Lim, E., Benafif, S., Russell, P., Boleti, E., Krebs, Matthew G, Lester, J. F., Papadatos-Pastos, D., Ahmad, T., Thakrar, R. M., Lawrence, D., Navani, N., Janes, S. M., Dive, Caroline, Blackhall, Fiona H, Summers, Yvonne J, Cave, J., Marafioti, T., Herrero, J., Quezada, S. A., Peggs, K. S., Schwarz, R. F., Van Loo, P., Miedema, D. M., Birkbak, N. J., Hiley, C. T., Hackshaw, A., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C.

المساهمون: Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

العلاقة: https://dx.doi.org/10.1038/s41586-023-05783-5Test; Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-33. PubMed PMID: 37046096. Pubmed Central PMCID: PMC10115649 for tumour monitoring (PCT/EP2022/077987). M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher, Takeda, Amgen, Janssen, MIM Software, Bristol-Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is a co-inventor on a patent to detect molecules in a sample (US patent 10578620). G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca. C.A. is an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and under their terms of employment, C.A. is due a revenue share of any revenue generated from such licence(s). C.A. declares a patent application (PCT/US2017/028013) for methods to detect lung cancer. C.A. is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. D.B. reports personal fees from NanoString and AstraZeneca. He has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. R.R. is an employee of and has stock options in Achilles Therapeutics and holds a European patent on targeting neoantigens (PCT/EP2016/059401) and in determining HLA LOH (PCT/GB2018/052004). D.A.F. reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, MSD, GSK, personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. K.S.P. is a co-founder of Achilles Therapeutics. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. E.L. has received funding from AstraZeneca, Boehringer Ingelheim, Medela, Johnson & Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, Boehringer Ingelheim and Bayer. E.L. has received consulting fees from Beigene, Roche and BMS, honoraria from Medela and is a founder My Cancer Companion, Healthcare Companion Ltd. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the past 3 years from AstraZeneca, Bard1 Lifescience and Johnson & Johnson. He has received a grant income from Owlstone and GRAIL Inc. He has received assistance with travel to an academic meeting from Cheisi. C.D. has received research funding and educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has also received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. J.C. reports funding from Amgen to attend a conference. A. Hackshaw has received fees for being a member of Independent Data Monitoring Committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912), has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and is a co-inventor on a patent for methods for predicting anticancer responses (US14/466,208). C.T.H. has received speaker fees from AstraZeneca. M.J.-H. has consulted for and is a member of the Achilles Therapeutics Scientific Advisory Board (SAB) and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent (PCT/US2017/028013) relating to methods for lung cancer detection. This patent has been licensed to commercial entities and under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx (collaboration in minimal residual disease sequencing technologies)) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s SAB. He receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre–Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is an inventor on a European patent application relating to an assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and under his terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient responses to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying indel mutation targets (PCT/GB2018/051892) and is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.S. is a named inventor on a provisional patent related to a ctDNA detection algorithm. Epub 2023/04/13. eng.; http://hdl.handle.net/10541/626225Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05783-5Test
http://hdl.handle.net/10541/626225Test

المؤلفون: Lechner M., Takahashi Y., Turri-Zanoni M., Liu J., Counsell N., Hermsen M., Kaur R. P., Zhao T., Ramanathan M., Schartinger V. H., Emanuel O., Helman S., Varghese J., Dudas J., Riechelmann H., Sprung S., Haybaeck J., Howard D., Engel N. W., Stewart S., Brooks L., Pickles J. C., Jacques T. S., Fenton T. R., Williams L., Vaz F. M., O'Flynn P., Stimpson P., Wang S., Hannan S. A., Unadkat S., Hughes J., Dwivedi R., Forde C. T., Randhawa P., Gane S., Joseph J., Andrews P. J., Royle G., Franchi A., Maragliano R., Battocchio S., Bewicke-Copley H., Pipinikas C., Webster A., Thirlwell C., Ho D., Teschendorff A., Zhu T., Steele C. D., Pillay N., Vanhaesebroeck B., Mohyeldin A., Fernandez-Miranda J., Park K. W., Le Q. -T., West R. B., Saade R., Manes R. P., Omay S. B., Vining E. M., Judson B. L., Yarbrough W. G., Sansovini M., Silvia N., Grassi I., Bongiovanni A., Capper D., Schuller U., Thavaraj S., Sandison A., Surda P., Hopkins C., Ferrari M., Mattavelli D., Rampinelli V., Facchetti F., Nicolai P., Bossi P., Henriquez O. A., Magliocca K., Solares C. A., Wise S. K., Llorente J. L., Patel Z. M., Nayak J. V., Hwang P. H., Lacy P. D., Woods R., O'Neill J. P., Jay A., Carnell D., Forster M. D., Ishii M., London N. R., Bell D. M., Gallia G. L., Castelnuovo P., Severi S., Lund V. J., Hanna E. Y.

المساهمون: Lechner, M., Takahashi, Y., Turri-Zanoni, M., Liu, J., Counsell, N., Hermsen, M., Kaur, R. P., Zhao, T., Ramanathan, M., Schartinger, V. H., Emanuel, O., Helman, S., Varghese, J., Dudas, J., Riechelmann, H., Sprung, S., Haybaeck, J., Howard, D., Engel, N. W., Stewart, S., Brooks, L., Pickles, J. C., Jacques, T. S., Fenton, T. R., Williams, L., Vaz, F. M., O'Flynn, P., Stimpson, P., Wang, S., Hannan, S. A., Unadkat, S., Hughes, J., Dwivedi, R., Forde, C. T., Randhawa, P., Gane, S., Joseph, J., Andrews, P. J., Royle, G., Franchi, A., Maragliano, R., Battocchio, S., Bewicke-Copley, H., Pipinikas, C., Webster, A., Thirlwell, C., Ho, D., Teschendorff, A., Zhu, T., Steele, C. D., Pillay, N., Vanhaesebroeck, B., Mohyeldin, A., Fernandez-Miranda, J., Park, K. W., Le, Q. -T., West, R. B., Saade, R., Manes, R. P., Omay, S. B., Vining, E. M., Judson, B. L., Yarbrough, W. G., Sansovini, M., Silvia, N., Grassi, I., Bongiovanni, A., Capper, D., Schuller, U., Thavaraj, S., Sandison, A., Surda, P., Hopkins, C., Ferrari, M., Mattavelli, D., Rampinelli, V., Facchetti, F., Nicolai, P., Bossi, P., Henriquez, O. A., Magliocca, K., Solares, C. A., Wise, S. K., Llorente, J. L., Patel, Z. M., Nayak, J. V., Hwang, P. H., Lacy, P. D., Woods, R., O'Neill, J. P., Jay, A., Carnell, D., Forster, M. D., Ishii, M., London, N. R., Bell, D. M., Gallia, G. L., Castelnuovo, P., Severi, S., Lund, V. J.

مصطلحات موضوعية: Adjuvant, Diagnostic imaging, Esthesioneuroblastoma, Human, Olfactory, Prognosi, Radiotherapy, Receptor, Somatostatin, SSTR2 protein

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34980502; info:eu-repo/semantics/altIdentifier/wos/WOS:000796006400024; volume:162; firstpage:221; lastpage:236; numberofpages:16; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11568/1132326Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85122345357

الإتاحة: https://doi.org/10.1016/j.ejca.2021.09.046Test
https://hdl.handle.net/11568/1132326Test

المؤلفون: Lechner M., Takahashi Y., Turri-Zanoni M., Ferrari M., Liu J., Counsell N., Mattavelli D., Rampinelli V., Vermi W., Lombardi D., Saade R., Park K. W., Schartinger V. H., Franchi A., Facco C., Sessa F., Battocchio S., Fenton T. R., Vaz F. M., O'Flynn P., Howard D., Stimpson P., Wang S., Hannan S. A., Unadkat S., Hughes J., Dwivedi R., Forde C. T., Randhawa P., Gane S., Joseph J., Andrews P. J., Dave M., Fleming J. C., Thomson D., Zhu T., Teschendorff A., Royle G., Steele C., Jimenez J. E., Laco J., Wang E. W., Snyderman C., Lacy P. D., Woods R., O'Neill J. P., Saraswathula A., Kaur R. P., Zhao T., Ramanathan M., Gallia G. L., London N. R., Le Q. -T., West R. B., Patel Z. M., Nayak J. V., Hwang P. H., Hermsen M., Llorente J., Facchetti F., Nicolai P., Bossi P., Castelnuovo P., Jay A., Carnell D., Forster M. D., Bell D. M., Lund V. J., Hanna E. Y.

المساهمون: Lechner, M., Takahashi, Y., Turri-Zanoni, M., Ferrari, M., Liu, J., Counsell, N., Mattavelli, D., Rampinelli, V., Vermi, W., Lombardi, D., Saade, R., Park, K. W., Schartinger, V. H., Franchi, A., Facco, C., Sessa, F., Battocchio, S., Fenton, T. R., Vaz, F. M., O'Flynn, P., Howard, D., Stimpson, P., Wang, S., Hannan, S. A., Unadkat, S., Hughes, J., Dwivedi, R., Forde, C. T., Randhawa, P., Gane, S., Joseph, J., Andrews, P. J., Dave, M., Fleming, J. C., Thomson, D., Zhu, T., Teschendorff, A., Royle, G., Steele, C., Jimenez, J. E., Laco, J., Wang, E. W., Snyderman, C., Lacy, P. D., Woods, R., O'Neill, J. P., Saraswathula, A., Kaur, R. P., Zhao, T., Ramanathan, M., Gallia, G. L., London, N. R., Le, Q. -T., West, R. B., Patel, Z. M., Nayak, J. V., Hwang, P. H., Hermsen, M., Llorente, J., Facchetti, F., Nicolai, P., Bossi, P., Castelnuovo, P., Jay, A., Carnell, D., Forster, M. D., Bell, D. M., Lund, V. J., Hanna, E. Y.

مصطلحات موضوعية: sinonasal mucosal melanoma, TNM, immunotherapy, immune checkpoint blockade, immune checkpoint inhibitors ipilimumab

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000822748800001; volume:-; journal:JOURNAL OF NEUROLOGICAL SURGERY. PART B, SKULL BASE; https://hdl.handle.net/11383/2139792Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85134744413

الإتاحة: https://doi.org/10.1055/s-0042-1750178Test
https://hdl.handle.net/11383/2139792Test

المؤلفون: Desai, J., Han, S. W., Forster, M. D., Kim, T. W., Casal, G. A., Shmueli, E. S., Bowyer, S. E., De Miguel, M. J., Gonzalez, A. F., Jones, R. H., Krebs, Matthew G, Miller, W. H., Paz-Ares, L., Lorusso, P., Sacher, A., Dharia, N., Lin, M. T., Schutzman, J. L., Shi, Z., Patel, M.

المساهمون: Medical Oncology Department, Peter MacCallum Cancer Centre, Melbourne, VIC,Australia

العلاقة: https://dx.doi.org/10.1016/annonc/annonc1048Test; Desai J, Han SW, Forster MD, Kim TW, Casal GA, Shmueli ES, et al. Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation. Annals of Oncology. 2022 Sep;33(7):S701-S2. PubMed PMID: WOS:000866211600356.; http://hdl.handle.net/10541/625952Test; Annals of Oncology

الإتاحة: https://doi.org/10.1016/annonc/annonc1048Test
http://hdl.handle.net/10541/625952Test

المؤلفون: Dillon, M. T., Boylan, Z., Smith, D., Guevara, J., Mohammed, K., Peckitt, C., Saunders, M., Banerji, U., Clack, G., Smith, S. A., Spicer, J. F., Forster, M. D., Harrington, K. J.

المصدر: Dillon , M T , Boylan , Z , Smith , D , Guevara , J , Mohammed , K , Peckitt , C , Saunders , M , Banerji , U , Clack , G , Smith , S A , Spicer , J F , Forster , M D & Harrington , K J 2018 , ' PATRIOT : A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours ....

مصطلحات موضوعية: ATR inhibition, Clinical trial, DNA damage response, Phase I, Radiosensitization

الإتاحة: https://doi.org/10.1016/j.ctro.2018.06.001Test
https://kclpure.kcl.ac.uk/portal/en/publications/17c9c7ff-ea34-4fef-8f21-3c7d5fed11f4Test
http://www.scopus.com/inward/record.url?scp=85061609547&partnerID=8YFLogxKTest